JP6283674B2 - 外膜小胞 - Google Patents

外膜小胞 Download PDF

Info

Publication number
JP6283674B2
JP6283674B2 JP2015531610A JP2015531610A JP6283674B2 JP 6283674 B2 JP6283674 B2 JP 6283674B2 JP 2015531610 A JP2015531610 A JP 2015531610A JP 2015531610 A JP2015531610 A JP 2015531610A JP 6283674 B2 JP6283674 B2 JP 6283674B2
Authority
JP
Japan
Prior art keywords
omv
protein
heterologous
heterologous protein
coli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015531610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535812A (ja
JP2015535812A5 (cg-RX-API-DMAC7.html
Inventor
グランディ, グイド
グイド グランディ,
イ ロス, イマクラーダ マルガリート
イ ロス, イマクラーダ マルガリート
エミリアーノ キアロット,
エミリアーノ キアロット,
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2015535812A publication Critical patent/JP2015535812A/ja
Publication of JP2015535812A5 publication Critical patent/JP2015535812A5/ja
Application granted granted Critical
Publication of JP6283674B2 publication Critical patent/JP6283674B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2015531610A 2012-09-18 2013-09-18 外膜小胞 Expired - Fee Related JP6283674B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261702296P 2012-09-18 2012-09-18
US61/702,296 2012-09-18
US201361799311P 2013-03-15 2013-03-15
US61/799,311 2013-03-15
PCT/EP2013/069415 WO2014044728A1 (en) 2012-09-18 2013-09-18 Outer membrane vesicles

Publications (3)

Publication Number Publication Date
JP2015535812A JP2015535812A (ja) 2015-12-17
JP2015535812A5 JP2015535812A5 (cg-RX-API-DMAC7.html) 2016-11-10
JP6283674B2 true JP6283674B2 (ja) 2018-02-21

Family

ID=49237191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015531610A Expired - Fee Related JP6283674B2 (ja) 2012-09-18 2013-09-18 外膜小胞

Country Status (9)

Country Link
US (1) US9764027B2 (cg-RX-API-DMAC7.html)
EP (3) EP4056198A3 (cg-RX-API-DMAC7.html)
JP (1) JP6283674B2 (cg-RX-API-DMAC7.html)
CN (1) CN104602702B (cg-RX-API-DMAC7.html)
AU (1) AU2013320313B2 (cg-RX-API-DMAC7.html)
CA (1) CA2882382A1 (cg-RX-API-DMAC7.html)
MX (1) MX363529B (cg-RX-API-DMAC7.html)
RU (1) RU2662970C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014044728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2097102T1 (sl) * 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
US10709776B2 (en) 2014-04-07 2020-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing outer membrane vesicles
WO2015169773A2 (en) * 2014-05-07 2015-11-12 Glaxosmithkline Biologicals S.A. Mutants of spy0269
KR101742236B1 (ko) * 2014-10-29 2017-05-31 인하대학교 산학협력단 쯔쯔가무시병에 대한 면역 조성물 및 이의 제조방법
BR112017025954A2 (pt) * 2015-06-02 2018-08-14 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport apresentação em superfície de antígenos em vesículas de membrana externa gram-negativa
CN105861402B (zh) * 2015-07-20 2020-02-14 中国医学科学院医学生物学研究所 将异源蛋白呈递于大肠杆菌外膜囊泡表面的新型疫苗形式
CN106866804B (zh) * 2015-12-11 2021-03-05 中国科学院植物研究所 一种与植物光合作用相关的cam01蛋白及其编码基因和应用
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
GB201607510D0 (en) * 2016-04-29 2016-06-15 Inst Of Food Res The Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (OMV) for delivery to the GI-tract
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
HUE052751T2 (hu) * 2016-11-25 2021-05-28 Glaxosmithkline Biologicals Sa Natív OMV-antigén konjugátumok és alkalmazásuk
CN110891599A (zh) * 2017-03-31 2020-03-17 印度医学研究理事会 基于来自伤寒样沙门菌物种的两种不同菌株的外膜囊泡的肠热疫苗
WO2018213242A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
GB201708277D0 (en) * 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
US11123415B2 (en) * 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
CA3096849A1 (en) * 2018-04-10 2019-10-17 The Administrators Of The Tulane Educational Fund Burkholderia pseudomallei complex outer membrane vesicles as adjuvants
CN109554311B (zh) * 2018-12-18 2022-01-14 中国农业科学院兰州兽医研究所 一种鼠伤寒沙门氏菌外膜囊泡的提取方法
JP2022520999A (ja) * 2019-02-22 2022-04-04 エヴェロ バイオサイエンシズ,インコーポレーテッド 細菌の膜調製物
EP3960191A4 (en) * 2019-04-26 2023-01-04 MD Healthcare Inc. PROTEIN DERIVED FROM STREPTOCOCCUS PYOGENES BACTERIA AND ITS USE
CN110272910A (zh) * 2019-06-25 2019-09-24 四川农业大学 一种包括jev抗原基因的重组载体、重组菌株和递呈jev抗原的外膜囊泡及其应用
WO2021031270A1 (zh) * 2019-08-22 2021-02-25 四川大学 细菌膜囊泡及其分离制备系统和方法
JP2023511305A (ja) 2020-01-17 2023-03-17 ウニベルシテ カソリーク デ ルーベン 変化したエンベロープ完全性を有する遺伝子組換え細菌およびその使用
CN115175697A (zh) * 2020-02-18 2022-10-11 Vaxcyte公司 具有多糖-蛋白质缀合物的a组链球菌免疫原性组合物
WO2022026896A2 (en) * 2020-07-30 2022-02-03 Omvax, Inc. Sars-cov-2 receptor binding domain in native outer membrane vesicles
CN117065041B (zh) * 2023-04-04 2024-02-27 山东大学 一种包被载药脂质纳米粒的外膜囊泡及其制备方法和应用
CN116622608A (zh) * 2023-05-31 2023-08-22 华中科技大学 一种诱导自裂解型抗抑郁工程菌株及其应用
US12649150B2 (en) 2024-05-29 2026-06-09 Cassiopea LLC Enzyme-decorated nanocatalysts
CN119932075A (zh) * 2025-01-25 2025-05-06 四川大学 一种携带外源蛋白的重组单增李斯特菌膜囊泡及其制备方法和应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0710118T3 (da) 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
JP2001510169A (ja) 1997-07-17 2001-07-31 ノース アメリカン ワクチン, インコーポレイテッド B型髄膜炎菌性ポーリンおよびH.influenzae多糖体を含む免疫原性結合体
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CN1200730C (zh) 1998-02-12 2005-05-11 惠氏控股有限公司 用白细胞介素-12配制的肺炎球菌和脑膜炎球菌疫苗
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003018054A1 (en) 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
RU2364418C2 (ru) * 2002-08-02 2009-08-20 ГлаксоСмитКлайн Байолоджикалз с.а. ВАКЦИННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЛИПОПОЛИСАХАРИДЫ ИММУНОТИПА L2 И/ИЛИ L3, ПРОИСХОДЯЩИЕ ИЗ ШТАММА NEISSERIA MENINGITIDIS IgtB-
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
AU2003288558A1 (en) 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
US7628995B2 (en) 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
AU2006235045A1 (en) 2005-03-30 2006-10-19 J. Craig Venter Institute, Inc. Haemophilus influenzae type b
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
AU2006259858A1 (en) 2005-05-12 2006-12-28 Novartis Vaccines And Diagnostics S.R.L. Immunogenic compositions for Chlamydia trachomatis
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP1954306A2 (en) 2005-10-25 2008-08-13 Novartis Vaccines and Diagnostics S.r.l. Compositions comprising yersinia pestis antigens
EP2292647A3 (en) * 2006-07-07 2011-06-08 Intercell AG Small Streptococcus pyogenes antigens and their use
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0717187D0 (en) 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
WO2009109860A2 (en) 2008-03-06 2009-09-11 Novartis Ag Mutant forms of chlamydia htra
MX2010012999A (es) 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
KR101042541B1 (ko) 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 g(-) 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법
GB0816284D0 (en) 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
HRP20160306T1 (hr) * 2008-09-17 2016-04-22 Glaxosmithkline Biologicals S.A. Kombinacija cjepiva i terapijskih sredstava protiv gas
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2012020326A1 (en) * 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
GB201009861D0 (en) * 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
CN103533954B (zh) * 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗

Also Published As

Publication number Publication date
MX2015002484A (es) 2015-06-05
CA2882382A1 (en) 2014-03-27
EP4056198A2 (en) 2022-09-14
RU2662970C2 (ru) 2018-07-31
MX363529B (es) 2019-03-27
EP2897635A1 (en) 2015-07-29
US9764027B2 (en) 2017-09-19
JP2015535812A (ja) 2015-12-17
EP3400960A1 (en) 2018-11-14
US20150231232A1 (en) 2015-08-20
RU2015106917A (ru) 2016-11-10
WO2014044728A1 (en) 2014-03-27
AU2013320313B2 (en) 2018-07-12
CN104602702B (zh) 2021-08-27
CN104602702A (zh) 2015-05-06
EP4056198A3 (en) 2022-12-07
AU2013320313A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
RU2662970C2 (ru) Везикулы наружной мембраны
US11026890B2 (en) Oil-in-water emulsions that contain nucleic acids
JP5908477B2 (ja) タンパク質をコードするrnaのリポソームによる送達に適した脂質
RU2625546C2 (ru) Катионные эмульсии "масло-в-воде"
RU2628705C2 (ru) Пегилированные липосомы для доставки кодирующей иммуноген рнк
ES2732893T3 (es) Administración de ARN autorreplicante utilizando partículas de polímeros biodegradables
US12054521B2 (en) FhuD2 fusion proteins for the outer membrane vesicle (OMV) delivery of heterologous polypetides and immunogenic compositions thereof
Patel et al. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines
CN105163724A (zh) 包含囊泡的药物组合物
WO2012129483A1 (en) Adjuvant nanoemulsions with phospholipids
JP2013530245A (ja) 低用量のrnaを用いた大型哺乳動物の免疫化
EP2729168A2 (en) Immunogenic compositions and uses thereof
EP3191123B1 (en) Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
US10286056B2 (en) Adjuvant nanoemulsions with crystallisation inhibitors
US20130101629A1 (en) Homogenous suspension of immunopotentiating compounds and uses thereof
JP2016520040A (ja) 膜抗原のための汎用化されたモジュールの産生用の変異細菌
HK40074942A (en) Outer membrane vesicles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160916

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180129

R150 Certificate of patent or registration of utility model

Ref document number: 6283674

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees